Jersey City's Synchrony Medical Raises $5M to Expand Respiratory Device Access

Synchrony Medical, a respiratory care technology company headquartered in Jersey City, closed an oversubscribed $5 million funding round to accelerate expansion of its FDA-cleared airway clearance system, the company announced Feb. 18.

Edge Medical Ventures led the investment round, with participation from the New Jersey Economic Development Authority (NJEDA), Broadfin Holdings, Consensus Business Group (CBG), and angel investors, according to the company. The funding will support U.S. commercial expansion, ongoing clinical research and product development, and broader patient access to Synchrony’s LibAirty Airway Clearance System.

The LibAirty system targets the millions of Americans living with chronic lung conditions who require airway clearance to manage symptoms, prevent infections, and slow disease progression. According to the company, about 4.2% of U.S. adults have been diagnosed with COPD, emphysema, or chronic bronchitis.

Synchrony Medical said its LibAirty system delivers therapy through daily home treatment that has demonstrated the ability to clear twice as much sputum as conventional therapies while providing enhanced user comfort and satisfaction. The company commercially launched the system in late 2025.

“This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health,” said Anat Shani, CEO of Synchrony Medical, which maintains operations in Or Yehuda, Israel, in addition to its Jersey City headquarters.

The investment comes with significant New Jersey support. The NJEDA contributed $1 million through the New Jersey Innovation Evergreen Fund’s co-investment with Edge Medical Ventures, according to the company. This state backing further reinforces Synchrony’s commitment to expanding its presence in New Jersey.

“Supported by our exceptional investors and new board members, we’re well positioned to scale our U.S. market presence, expand our clinical evidence base, and advance product innovation,” Shani said.

The funding round brings new leadership to Synchrony’s board of directors. Kevin Kotler, general partner of Broadfin Holdings, and Elad Duschak, strategic adviser to CBG for Healthcare, joined the company’s board in conjunction with the investment, according to the announcement.

Synchrony plans to continue expanding its U.S. team and operations from its Jersey City headquarters, positioning the company to capitalize on growing demand for respiratory care technologies. The respiratory device market has seen increased attention as awareness grows around chronic lung conditions and the need for effective home-based treatments.

The LibAirty system represents a technological advancement in airway clearance therapy, offering patients a home-based solution that the company says outperforms traditional methods. For patients managing chronic respiratory conditions, effective airway clearance can be critical to maintaining quality of life and preventing complications that often lead to hospitalizations.

The successful funding round positions Synchrony Medical to scale its operations significantly as it works to bring its FDA-cleared technology to more patients across the United States. With strong investor backing including state support through the NJEDA, the Jersey City-based company appears well-positioned to expand its market presence in the growing respiratory care sector.

The company’s dual presence in New Jersey and Israel reflects the increasingly global nature of medical technology development, while its Jersey City headquarters anchors its U.S. commercial operations in the state’s growing life sciences corridor.